| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1.2M | +10.0% | +83.4% |
| SG&A Expense | $1.3M | +7.2% | +40.0% |
| Operating Income | -$2.5M | -8.5% | -57.5% |
| Net Income | -$2.4M | -10.4% | -57.0% |
| EPS (Basic) | -$0.44 | +2.2% | +71.4% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $10.7M | -0.6% | +98.6% |
| Current Assets | $11.5M | +1.8% | +96.0% |
| Total Assets | $11.5M | +1.8% | +96.2% |
| Total Liabilities | $1.7M | +38.1% | — |
| Stockholders' Equity | $9.8M | -2.5% | +98.9% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$5.9M | — | — |
| Capital Expenditures | $12K | — | — |
| Investing Cash Flow | -$12K | — | — |
| Financing Cash Flow | $11.2M | — | — |
| Free Cash Flow | -$5.9M | — | — |